SCHEMBL10242925

SCHEMBL10242925

CCCNC(=O)Cc1cccc(-c2cccnc2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 2/20 0.53
PRMT6 Q96LA8 1/20 0.53
LMNA P02545 1/20 0.50
IDO1 P14902 1/20 0.49
CYP1A2 P05177 2/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2C9 P11712 1/20 0.49
PORCN Q9H237 1/20 0.47
ERCC1 P07992 1/20 0.46
ERCC4 Q92889 1/20 0.46
CYP4F2 P78329 1/20 0.46
CYP4A11 Q02928 1/20 0.46
KLKB1 P03952 1/20 0.46
KLK1 P06870 1/20 0.46
HTT P42858 1/20 0.46
CTSV O60911 1/20 0.46
CTSL P07711 1/20 0.46
CTSB P07858 1/20 0.46
CTSS P25774 1/20 0.46
WNT3A P56704 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1927063 0.84 TRPV1 (0.53) LMNAGAA
SCHEMBL934604 0.79 EPHX2 (0.63) EPHX2PRMT6LMNACYP1A2CYP3A4
SCHEMBL3933089 0.79 ALDH1A1 (0.60) EPHX2PRMT6PORCNKLKB1KLK1
SCHEMBL10242894 0.79 CYP4F2 (0.50) CYP1A2CYP4F2CYP4A11CTSLCTSB
SCHEMBL3941960 0.78 NAPRT (0.67) EPHX2PRMT6CYP1A2CYP3A4CTSV
SCHEMBL14987333 0.77 EPHX2 (0.50) EPHX2PRMT6LMNACYP1A2CYP3A4
SCHEMBL5215127 0.77 EPHX2 (0.50) EPHX2PRMT6CTSVCTSLCTSB
SCHEMBL5176875 0.76 EPHX2 (0.55) EPHX2PRMT6CYP1A2CYP3A4KLKB1
SCHEMBL9709514 0.76 EPHX2 (0.52) EPHX2PRMT6LMNACYP1A2CYP3A4
SCHEMBL947435 0.75 NAMPT (0.51) LMNAIDO1PORCNWNT3ANAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 EPHX2 2656/4885PRMT6 1751/4885LMNA 1467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.